Aktuelle News
News Funktionen
Weitere Funktionen
4 Januar 2023
Pharnext
Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
28 Dezember 2022
Pharnext
Pharnext strengthens its ties with Néovacs to secure the next steps in its development
28 November 2022
Pharnext
The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
22 November 2022
Pharnext
Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions
8 November 2022
Pharnext
Hugo Brugière Joins Pharnext Board of Directors
31 Oktober 2022
Pharnext
Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,
17 Oktober 2022
Pharnext
Pharnext Reports First Half 2022 Financial Results
3 Oktober 2022
Pharnext
Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext’s share capital including the conversions of convertible bonds
Pharnext
Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A
15 September 2022
Pharnext
Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia
14 September 2022
Pharnext
Pharnext: Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease
12 September 2022
Pharnext
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
1 September 2022
Pharnext
Pharnext Appoints Dr. Rob Quinn as Chief Financial Officer
23 August 2022
Pharnext
Pharnext Announces a €2.5m Loan Agreement with Néovacs
5 Juli 2022
Pharnext
Pharnext Appoints Antoine Gravelle as General Counsel
28 Juni 2022
Pharnext
Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022
20 Juni 2022
Pharnext
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors
8 Juni 2022
Pharnext
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
30 Mai 2022
Pharnext
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
17 Mai 2022
Pharnext
Pharnext: Tirage d’une onzième tranche de 300 obligations convertibles en actions
10 Mai 2022
Pharnext
Pharnext annonce la tenue de son assemblée générale annuelle mixte le 17 juin 2022 et une réduction de capital motivée par des pertes
5 Mai 2022
Pharnext
Pharnext: The Latest Findings From CMT&Me, a ‘Real-World’ Digital Lifestyle Study on Charcot-Marie-Tooth Diseases (‘CMTs’), to be Presented at the 2022 Peripheral Nerve Society (‘PNS’) Annual Meeting
25 April 2022
Pharnext
Pharnext: Tirage d’une dixième tranche de 300 obligations convertibles en actions
Pharnext
Pharnext: Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates
4 April 2022
Pharnext
Pharnext: Tirage d’une neuvième tranche de 300 obligations convertibles en actions
30 März 2022
Pharnext
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
15 März 2022
Pharnext
Pharnext: Tirage d’une huitième tranche de 300 obligations convertibles en actions
8 März 2022
Pharnext
Pharnext: Assemblée Générale Extraordinaire fixée au 21 mars 2022
28 Februar 2022
Pharnext
Pharnext: Report de l’assemblée générale extraordinaire des actionnaires du 28 février 2022
15 Februar 2022
Pharnext
Pharnext appoints Valérie Worrall as Chief Financial Officer